316 filings
Page 2 of 16
S-8 POS
m41sb 9kx
16 Oct 23
Registration of securities for employees (post-effective amendment)
1:56pm
S-8 POS
tposk
16 Oct 23
Registration of securities for employees (post-effective amendment)
1:55pm
S-8 POS
3u780hmr
16 Oct 23
Registration of securities for employees (post-effective amendment)
1:54pm
8-K
cy1mc0wafn
13 Oct 23
Departure of Directors or Certain Officers
10:30am
8-K
el0esvktjp9k
13 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:45am
8-K
3n0mgll1v3rcaau we01
7 Aug 23
Departure of Directors or Certain Officers
4:05pm
8-K
95sp8uy8m8fyn
24 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:10pm
8-K
6uocm7a54
20 Jul 23
Departure of Directors or Certain Officers
4:05pm
8-K
iy6 548vu
14 Jul 23
Departure of Directors or Certain Officers
4:05pm
8-K
iwm31fkxzmis
29 Jun 23
Cost Associated with Exit or Disposal Activities
4:06pm
EFFECT
gyvnv
12 Jun 23
Notice of effectiveness
12:15am
8-K
rhh zwi7syxvlpq2
9 Jun 23
Departure of Directors or Certain Officers
4:05pm
CORRESP
cu2x5
8 Jun 23
Correspondence with SEC
12:00am
S-8
6f1 hzrb5mf
7 Jun 23
Registration of securities for employees
5:06pm
UPLOAD
3xm6xo07
7 Jun 23
Letter from SEC
12:00am
8-K
a9q f416b
5 Jun 23
Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
8:08am
424B5
avjim 9yel2
31 May 23
Prospectus supplement for primary offering
4:40pm
8-K
bsu5jqelpaj6 pi316i
15 May 23
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
4:54pm